ProKidney Corp. (NASDAQ:PROK – Get Free Report) SVP Darin J. Weber sold 16,438 shares of the business’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $2.51, for a total transaction of $41,259.38. Following the transaction, the senior vice president now directly owns 155,194 shares of the company’s stock, valued at approximately $389,536.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
ProKidney Stock Performance
Shares of PROK opened at $2.53 on Wednesday. ProKidney Corp. has a 1 year low of $1.12 and a 1 year high of $13.51. The firm has a fifty day moving average of $1.63 and a 200-day moving average of $1.74. The company has a market cap of $580.24 million, a price-to-earnings ratio of -4.44 and a beta of 1.08.
ProKidney (NASDAQ:PROK – Get Free Report) last issued its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Analysts predict that ProKidney Corp. will post -0.65 EPS for the current year.
Institutional Investors Weigh In On ProKidney
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on PROK shares. Bank of America downgraded shares of ProKidney from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd. Morgan Stanley started coverage on shares of ProKidney in a report on Thursday, March 7th. They set an “equal weight” rating and a $3.00 price target for the company.
Check Out Our Latest Research Report on PROK
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Featured Articles
- Five stocks we like better than ProKidney
- 3 Fintech Stocks With Good 2021 Prospects
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Investing in Travel Stocks Benefits
- Lockheed Martin Stock Aims for a Fresh All-Time High
- How to Find Undervalued Stocks
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.